<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154788">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02005991</url>
  </required_header>
  <id_info>
    <org_study_id>B2081015</org_study_id>
    <nct_id>NCT02005991</nct_id>
  </id_info>
  <brief_title>A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377</brief_title>
  <official_title>A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will see how PF-05212377, an experimental drug to treat symptoms from Alzheimer's
      Disease, distributes in the brain after one dose of PF-05212377 is administered orally to
      healthy volunteer subjects. The study will also evaluate the safety and tolerability of
      PF-05212377 in these subjects and will measure the level of PF-05212377 in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>5-HT2a receptor occupancy of PF-05212377 in the frontal cortex using PET</measure>
    <time_frame>Days 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PF-05212377 exposure associated with PF-05212377 5-HT2a receptor occupancy</measure>
    <time_frame>Days 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-HT2a receptor occupancy of PF-05212377 in other cortical regions</measure>
    <time_frame>Day 1 and 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-05212377 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05212377 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05212377 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212377</intervention_name>
    <description>Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.</description>
    <arm_group_label>PF-05212377 70 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212377</intervention_name>
    <description>Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation.  This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.</description>
    <arm_group_label>PF-05212377 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212377</intervention_name>
    <description>Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation.  This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.</description>
    <arm_group_label>PF-05212377 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females must be at least 18 years of age and no older than 55 years of age
             with a Body Mass Index (BMI) must be between 17.5 and 30.5.

          -  Subjects must sign a consent form and comply with all scheduled visits, treatment
             plan, lab tests and other study procedures.

        Exclusion Criteria:

          -  Females must not be pregnant, breastfeeding, or able to have children.

          -  Subjects must not have a severe acute or chronic medical or psychiatric condition
             history or evidence of blood, kidney, glandular, lung, stomach, intestine, heart,
             blood vessel, liver, psychiatric, nerve, or allergic problems (including drug
             allergies), except mild seasonal allergies.

          -  Subjects must not drink alcohol excessively or take illicit drugs.

          -  Male subjects use condoms to prevent the potential transfer of drug through the semen
             to their partner beginning with the dose of study drug and use a highly effective
             method of birth control with any partner(s) of childbearing potential through 28 days
             after the last dose.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2081015&amp;StudyName=A%20Study%20To%20Examine%20The%20Distribution%20Of%20PF-05212377%20In%20The%20Brain%20Of%20Healthy%20Volunteer%20Subjects%20Using%20Positron%20Emission%20Tomography%20And%20A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-05212377</keyword>
  <keyword>phase 1</keyword>
  <keyword>open-label</keyword>
  <keyword>5-HT2a receptor occupancy</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>brain</keyword>
  <keyword>cortex</keyword>
  <keyword>alzheimers disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
